


PHARMACEUTICAL 2021



ALX ONCOLOGY HOLDINGS INC Rank 37 of 409





RealRate

PHARMACEUTICAL 2021



ALX ONCOLOGY HOLDINGS INC Rank 37 of 409

The relative strengths and weaknesses of ALX ONCOLOGY HOLDINGS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ALX ONCOLOGY HOLDINGS INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 222% points. The greatest weakness of ALX ONCOLOGY HOLDINGS INC is the variable Revenues, reducing the Economic Capital Ratio by 33% points.

The company's Economic Capital Ratio, given in the ranking table, is 130%, being 485% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	435,992
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,204
Liabilities, Non-Current	5.0
Other Assets	10
Other Compr. Net Income	0
Other Expenses	1,720
Other Liabilities	0
Other Net Income	-1,432
Property and Equipment	52
Research and Development	28,961
Revenues	1,182
Selling, General and Administrative Expense	14,809

Output Variable	Value in 1000 USD
Assets	436,054
Liabilities	6,209
Expenses	45,490
Stockholders Equity	429,845
Net Income	-45,740
Comprehensive Net Income	-45,740
Economic Capital Ratio	130%